Biotech rivals clash as Arrowhead sues Ionis over RNA-based triglyceride therapy

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has filed a declaratory judgment complaint in the U.S. District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), escalating a patent dispute that could determine the commercial future of its lead RNA interference therapy, plozasiran. The complaint, filed on September 10, 2025, seeks a ruling that Ionis’s U.S. Patent No. 9,593,333—referred to in court filings as the ’333 patent—is both invalid and not infringed by Arrowhead’s investigational therapy.

Arrowhead’s legal move comes as plozasiran approaches its FDA decision date, following a string of successful trials in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG). The RNAi therapeutic has been granted Breakthrough Therapy Designation, Fast Track status, and Orphan Drug designations by U.S. and European regulators. With commercialization on the horizon, the company is seeking to eliminate the looming intellectual property threat posed by Ionis, which has asserted infringement claims based on the ’333 patent.

According to Arrowhead’s filing, Ionis has alleged that plozasiran violates claims of the ’333 patent, which relates to the modulation of apolipoprotein C-III (APOC3) expression in lipoprotein lipase deficient populations. Arrowhead maintains that the patent is invalid and that its RNAi-based approach is fundamentally distinct from Ionis’s antisense oligonucleotide (ASO) platform, both in chemical structure and mechanism of action.

What is plozasiran and why is it important in the fight against severe lipid disorders?

Plozasiran, formerly known as ARO-APOC3, is Arrowhead’s most advanced clinical candidate and represents a new generation of RNAi therapeutics targeting lipid metabolism. The therapy is designed to reduce the hepatic production of APOC3, a key inhibitor of lipoprotein lipase and a central player in triglyceride homeostasis. Elevated APOC3 levels have been implicated in severe hypertriglyceridemia, pancreatitis, and atherosclerotic cardiovascular disease.

Unlike traditional small molecules or monoclonal antibodies, plozasiran utilizes the RNAi mechanism to silence gene expression post-transcriptionally. Arrowhead’s delivery system uses a proprietary targeted conjugate platform, optimized to deliver small interfering RNAs (siRNAs) directly to hepatocytes.

By knocking down APOC3 at the mRNA level, plozasiran has demonstrated profound reductions in triglyceride levels—over 90% in some early-stage trials. The therapy is being positioned not just for ultra-rare FCS but also for broader dyslipidemia indications. The FDA is expected to issue a decision on its approval for FCS before November 18, 2025.

How does Ionis Pharmaceuticals fit into the picture with Tryngolza?

Ionis Pharmaceuticals, headquartered in Carlsbad, California, is a pioneer in the antisense oligonucleotide space and holds a broad IP portfolio covering gene silencing approaches, including targeting of APOC3. Its commercialized product, Tryngolza (olezarsen), was approved by the FDA in December 2024 for the treatment of FCS, giving Ionis a significant first-mover advantage in the rare lipid disorder market.

Tryngolza operates via a distinct mechanism—antisense inhibition of APOC3 mRNA—which reduces its translation into protein. However, Ionis believes that despite the platform differences, Arrowhead’s plozasiran infringes on its intellectual property due to overlap in the targeted biological pathway and patient populations.

With the launch of Tryngolza already underway, Ionis is also preparing to expand its indications into SHTG and mixed dyslipidemia, directly placing its product in competition with plozasiran should the latter gain regulatory approval. The timing and outcome of this lawsuit could significantly alter the commercial trajectories of both products.

Why did Arrowhead take pre-emptive legal action instead of waiting for Ionis to sue?

Arrowhead’s decision to initiate a declaratory judgment suit, rather than wait for Ionis to file a patent infringement case, reflects its intent to proactively remove any uncertainty surrounding plozasiran’s IP landscape. In its public statement, Arrowhead said Ionis had “repeatedly asserted” that Arrowhead’s commercialization of plozasiran would infringe the ’333 patent, which the company disputes as “without merit.”

Arrowhead is not seeking damages but rather a definitive ruling that the ’333 patent is invalid and unenforceable. It also emphasizes that plozasiran is covered by its own internally developed U.S. patents and was not derived from any Ionis intellectual property. The filing argues that Ionis’s claims are an attempt to stifle competition and preserve its commercial exclusivity around APOC3 inhibition, despite the fundamental platform differences between RNAi and ASO therapies.

The declaratory judgment filing marks a critical step in Arrowhead’s launch preparations, as patent overhangs can complicate regulatory approvals, commercialization timelines, and partnership negotiations. Removing legal ambiguity before plozasiran hits the market could allow Arrowhead to move forward with greater pricing flexibility, fewer royalty liabilities, and stronger negotiating power with payers and strategic collaborators.

What’s at stake for both companies in this litigation?

For Arrowhead Pharmaceuticals, the lawsuit is a pivotal moment. Plozasiran represents its most advanced pipeline asset, and the company’s valuation is heavily tied to the drug’s commercial prospects. A ruling in its favor would clear the runway for a clean launch and potentially establish Arrowhead as a leader in RNAi-based cardiometabolic therapies.

If, however, the court upholds the validity of Ionis’s ’333 patent and finds infringement, Arrowhead could be forced to license the IP, delay launch, or even shelve plozasiran depending on the court’s remedy. This would significantly reduce the asset’s value proposition and could impact investor confidence.

Ionis Pharmaceuticals, on the other hand, risks losing its competitive moat around APOC3 inhibition. While Tryngolza has already been approved, its exclusivity could be eroded if Arrowhead is allowed to enter the same space with a potentially more durable, less frequently dosed alternative. The outcome of this lawsuit could also affect Ionis’s broader IP enforcement strategy across other targets and programs.

How do the financials and market positioning of Arrowhead and Ionis compare?

Arrowhead Pharmaceuticals, despite a history of net losses, reported $572.98 million in trailing twelve-month revenue. Its Q2 FY25 results showed quarterly revenue of $542.7 million, buoyed by milestone payments from licensing deals, most notably a recent collaboration with Sarepta Therapeutics valued at over $825 million including upfront and equity investment components. This deal, combined with a healthy balance sheet, gives Arrowhead operational runway into at least 2028. However, the absence of product revenue means the commercial success of plozasiran is crucial to transitioning into a revenue-generating business.

Ionis Pharmaceuticals has entered a new phase with Tryngolza’s commercial launch. The company reported Q2 2025 revenue of approximately $452 million, nearly double year-on-year. Product sales contributed a growing share, with Tryngolza alone generating around $19 million in its first full quarter. Ionis raised its full-year guidance to a range of $825–850 million, indicating strong confidence in its pipeline and market adoption. With nearly $2 billion in cash and short-term investments, Ionis has ample financial firepower to support litigation, expansion, and R&D.

From an investor lens, Arrowhead is seen as a high-beta, high-upside play tied to binary regulatory and litigation outcomes, while Ionis is viewed as a maturing commercial-stage company with expanding revenue streams and a more diversified risk profile.

What is the early sentiment from analysts and institutional investors?

Initial analyst commentary has been cautious but focused. Most equity research shops see the lawsuit as a logical, if aggressive, strategic move by Arrowhead to de-risk its launch roadmap. Given the clear differences in drug platforms and the absence of any co-development history between the two firms, Arrowhead may have a strong case for non-infringement. However, the validity of the ’333 patent remains a separate legal question, and institutional investors are bracing for a prolonged legal timeline.

Investor sentiment around Ionis remains optimistic in the short term. The company has successfully transitioned into revenue-generating mode and demonstrated commercial execution with Tryngolza. Analysts tracking Ionis continue to rate it favorably, with some projecting that its lipid franchise could exceed $1.5 billion in annual sales if it expands beyond FCS.

For Arrowhead, the stock remains under watch. Buy ratings depend on two events materializing in its favor: a favorable court ruling and FDA approval of plozasiran. Until those risks resolve, sentiment remains neutral to cautiously bullish among biotech-focused institutional investors.

What does this case tell us about the future of RNA-based therapeutics and IP battles?

This dispute illustrates the growing overlap—and friction—between RNAi and antisense modalities, particularly as both mature into commercially viable platforms. Companies with legacy IP portfolios are increasingly encountering newer players whose innovations target the same biological pathways but via different technologies. The legal system will play an outsized role in defining how broad or narrow gene-targeting patents can be, and whether delivery mechanism differences are sufficient to distinguish infringing from non-infringing products.

With cardiovascular and metabolic conditions emerging as high-value indications for RNA-based drugs, particularly in orphan and high-unmet-need spaces, companies will continue to litigate aggressively to protect first-mover advantage. Whether the courts side with Arrowhead’s technical distinctions or Ionis’s broader pathway-based claims could shape future IP filings and deal structures across the sector.